This document is an excerpt from the EUR-Lex website
Document 62009TB0275
Case T-275/09: Order of the General Court of 4 July 2011 — Sepracor Pharmaceuticals v Commission (Action for annulment — Medicinal products for human use — Active substance eszopiclone — Marketing authorisation — Refusal of recognition as a new active substance — Act not amenable to review — Inadmissibility)
Case T-275/09: Order of the General Court of 4 July 2011 — Sepracor Pharmaceuticals v Commission (Action for annulment — Medicinal products for human use — Active substance eszopiclone — Marketing authorisation — Refusal of recognition as a new active substance — Act not amenable to review — Inadmissibility)
Case T-275/09: Order of the General Court of 4 July 2011 — Sepracor Pharmaceuticals v Commission (Action for annulment — Medicinal products for human use — Active substance eszopiclone — Marketing authorisation — Refusal of recognition as a new active substance — Act not amenable to review — Inadmissibility)
OJ C 282, 24.9.2011, p. 17–17
(BG, ES, CS, DA, DE, ET, EL, EN, FR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)
|
24.9.2011 |
EN |
Official Journal of the European Union |
C 282/17 |
Order of the General Court of 4 July 2011 — Sepracor Pharmaceuticals v Commission
(Case T-275/09) (1)
(Action for annulment - Medicinal products for human use - Active substance eszopiclone - Marketing authorisation - Refusal of recognition as a new active substance - Act not amenable to review - Inadmissibility)
2011/C 282/31
Language of the case: English
Parties
Applicant: Sepracor Pharmaceuticals (Ireland) Ltd (Dublin, Ireland) (represented by: I. Dodds-Smith, Solicitor, D. Anderson QC, and J. Stratford, Barrister)
Defendant: European Commission (represented by: A. Sipos, and subsequently by M. Wilderspin and M. Šimerdová, Agents)
Re:
ACTION for annulment of the decision in the letter of the Commission addressed to the applicant on 6 May 2009 in the context of the procedure for authorising the placing on the market of Lunivia, inasmuch as it concerns classification of the active substance eszopiclone
Operative part of the order
|
1. |
The action is dismissed as inadmissible. |
|
2. |
Sepracor Pharmaceuticals (Ireland) Ltd shall pay the costs. |